amphetamine - Profile

What are the generic sources for amphetamine and what is the scope of freedom to operate?

Amphetamine is the generic ingredient in thirty-one branded drugs marketed by Neos Theraps Inc, Neos Theraps, Actavis Labs Fl Inc, Teva, Takeda Pharms Usa, Actavis Elizabeth, Ani Pharms, Ascent Pharms Inc, Aurolife Pharma Llc, Elite Labs Inc, Granules, Impax Labs, Lannett Co Inc, Lupin, Nesher Pharms, Ph Health, Rhodes Pharms, Specgx Llc, Sun Pharm Inds Inc, Sun Pharm Industries, Teva Pharms Usa, Barr Labs Inc, Teva Womens, Accord Hlthcare, Alkem Labs Ltd, Alvogen, Barr, Cediprof Inc, Corepharma, Epic Pharma Llc, Nuvo Pharm, Oryza, Sandoz, Teva Pharms, Zydus Pharms, Ucb Inc, Azurity, Amneal Pharms, Bionpharma, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Ingenus Pharms Llc, Lannett, Prinston Inc, Sanaluz, Senores Pharms, and Tris Pharma Inc, and is included in seventy NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amphetamine has two patent family members in two countries.

There are two tentative approvals for this compound.

Summary for amphetamine

International Patents:	2
US Patents:	21
Tradenames:	31
Applicants:	47
NDAs:	70
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for amphetamine

Generic filers with tentative approvals for AMPHETAMINE

Applicant	Application No.	Strength	Dosage Form
		18.8MG	TABLET, ORALLY DISINTEGRATING;ORAL
		15.7MG	TABLET, ORALLY DISINTEGRATING;ORAL
		12.5MG	TABLET, ORALLY DISINTEGRATING;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for AMPHETAMINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADZENYS XR-ODT	Extended-release Orally Disintegrating Tablets	amphetamine	3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg	204326	1	2016-05-10

US Patents and Regulatory Information for amphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No	8,709,491		Y
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No	9,017,731		Y
Neos Theraps Inc	ADZENYS ER	amphetamine	SUSPENSION, EXTENDED RELEASE;ORAL	204325-001	Sep 15, 2017		DISCN	Yes	No	9,265,737		Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	AB	RX	Yes	No	8,709,491		Y
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	AB	RX	Yes	No	8,840,924		Y

Expired US Patents for amphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-002	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-006	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-001	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-004	Jan 27, 2016	8,840,924
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-003	Jan 27, 2016	8,840,924

International Patents for amphetamine

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622

Investment Scenario and Fundamentals Analysis for Amphetamine

Last updated: February 20, 2026

What Are the Market Dynamics for Amphetamine?

Amphetamine is a central nervous system stimulant primarily used for treating attention deficit hyperactivity disorder (ADHD) and narcolepsy. Its global market size was valued at approximately USD 1.8 billion in 2022. Growth is driven by rising ADHD diagnoses, approval of new formulations, and increased use in treatment protocols.

Key market drivers include aging populations, increasing mental health awareness, and regulatory approvals expanding indications. Challenges involve regulatory controls due to abuse potential, geopolitical risks affecting supply chains, and competition from alternative treatments such as non-stimulant medications.

How Is the Regulatory Environment Shaping Investment?

Amphetamine is classified as a Schedule II controlled substance in the United States under the Controlled Substances Act, indicating high abuse potential but recognized medical use. Similar classifications exist worldwide (e.g., Schedule II in Canada, Schedule 2 under the UN Single Convention).

Regulatory pathways for new formulations or delivery systems require rigorous approval processes:

• FDA Regulatory Process: Typically 8-10 months for new drug applications (NDAs), with additional time for clinical trials.
• Global Regulatory Variance: European Union regulators evaluate based on the European Medicines Agency (EMA) standards, with process durations comparable to the FDA.

Legal restrictions impact manufacturing, distribution, and prescribing practices, affecting revenue streams and investment risk.

How Do Patent and Intellectual Property Positions Influence Investment?

Existing patents on specific formulations or delivery methods for amphetamine products expire or are under challenge. For example:

• The original patents for Adderall (mixed amphetamine salts) expired in the early 2010s.
• Companies introducing novel formulations (e.g., extended-release, transdermal patches) seek new patents, offering market exclusivity for up to 20 years.

Patent expiration opens markets for generic manufacturers, increasing competition and reducing prices, impacting profit margins for original developers.

What Are the Competitive and Substitute Landscape?

Competition includes:

• Generic Manufacturers: Offer lower-cost equivalents post-patent expiry.
• Alternative Medications: Non-stimulant drugs such as atomoxetine, guanfacine, and clonidine gain acceptance for ADHD treatment.
• Reformulations: Extended-release and chronotherapy options.

Market share shifts depend on formulary inclusion, prescriber preferences, and patient response. Entry barriers are moderate for generics but high for innovative delivery systems with patent protection.

How Do Manufacturing and Supply Chain Factors Affect Investment?

Manufacturing amphetamine requires compliance with strict regulations, including:

• Secure facilities compliant with Good Manufacturing Practice (GMP).
• Import/export controls due to its controlled status.
• Supply chain stability impacted by geopolitical or regulatory disruptions, as seen with Iran or North Korea-based manufacturing.

Global shortages have occurred, affecting pricing and timing of product launches.

What Financial Metrics Are Relevant?

• Revenue: Monitored for branded versus generic segments.
• Profit Margins: Higher for patented formulations, decrease as patents expire.
• R&D Investment: Focused on novel formulations, alternative delivery, and abuse-deterrent versions.
• Market Penetration: Regional variations influence regional growth prospects.

Cost of capital remains high, with risks tied to regulatory hurdles and patent cliffs. Commercial focuses include expanding use in adult ADHD and exploring new indications such as cognitive enhancement.

What Are the Key Investment Risks?

• Regulatory Risks: Tightening controls can restrict access.
• Legal Risks: Litigation over abuse liability or patent infringement.
• Market Risks: Competitive pressures from generics and alternative therapies.
• Supply Risks: Disruptions in raw material supplies or manufacturing facilities.

Summary of Investment Fundamentals

Category	Details
Market Size	USD 1.8 billion (2022)
CAGR (2023-2030)	Estimated 4.2% growth, driven by ADHD prevalence and formulations
Patent Status	Expiry for major formulations; ongoing patent filings for new delivery methods
Regulatory Environment	Strict controls; regional regulatory variance; approval timelines vary
Competition	Generics, non-stimulants, reformulations
Supply Chain Risks	Geopolitical disruptions; raw material dependency

Key Takeaways

• The amphetamine market is mature, with growth driven by demographic and diagnostic trends.
• Patent expiries will erode margins, but innovations in formulations sustain exclusivity.
• Regulatory and legal environments pose substantial risks, especially related to abuse potential.
• Competition from generics and alternative therapies impacts profitability.
• Supply chain security and manufacturing compliance are critical for consistent revenue.

Frequently Asked Questions

1. What is the primary driver for amphetamine demand? Rising ADHD diagnosis and expanded indications.

2. How do patent expiries influence market entry? They enable generic competitors, reducing prices and profit margins for original developers.

3. Are there opportunities in reformulated amphetamine products? Yes; formulations with abuse-deterrent features can maintain market share.

4. What regulatory hurdles exist for new amphetamine formulations? Approval processes are lengthy and require extensive safety and efficacy data.

5. How does legal classification impact global availability? Controlled substance status limits manufacturing, distribution, and sales in many countries.

---

References

[1] Grand View Research. (2022). Amphetamine Market Size, Share, & Trends Analysis.
[2] U.S. Food and Drug Administration. (2022). Controlled Substances Schedule.
[3] European Medicines Agency. (2022). Regulatory Procedures for CNS Drugs.
[4] PatentScope. (2022). Patent statuses for amphetamine formulations.
[5] MarketWatch. (2023). ADHD Medications Market Outlook.